TMCnet News

Research and Markets: Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review & Analysis, H2 2015
[November 27, 2015]

Research and Markets: Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review & Analysis, H2 2015


Research and Markets (http://www.researchandmarkets.com/research/fzmftp/acute_renal) has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects.

Key Topics Covered:

  • Snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • Key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all heir major and minor projects
  • All dormant and discontinued pipeline projects
  • All Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • Detailed assessment of monotherapy and combination therapy pipeline projects



Benefits of this Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned Include:


  • A1M Pharma AB
  • Adrenomed AG
  • Am-Pharma B.V.
  • Angion Biomedica Corp.
  • Bolder Biotechnology, Inc.
  • Cellmid Limited
  • Complexa, Inc.
  • DiaMedica Inc.
  • Digna Biotech, S.L.
  • DURECT Corporation
  • F. Hoffmann-La Roche Ltd.
  • STATegics, Inc.
  • Thrasos, Inc.
  • Torrent Pharmaceuticals Limited

For more information visit http://www.researchandmarkets.com/research/fzmftp/acute_renal


[ Back To TMCnet.com's Homepage ]